Due to health issues, this site is no longer maintained and will be shut down shortly.

SLRX Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals, Inc. a clinical-stage oncology company, develops therapies for the treatment of patients with various cancers. The company's lead candidate is Seclidemstat, which is in clinical development for the treatment of Ewing sarcoma, as well as advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.

$2.11  +0.06 (2.93%)
As of 03/24/2023 16:30:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  01/29/2015
Outstanding shares:  2,278,227
Average volume:  16,560
Market cap:   $4,670,365
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy